![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 27, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
January 30, 2026
This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments
November 21, 2025
This clinical trial is exploring whether PARP inhibitors will improve outcomes for patients with early-stage pancreas cancer that has BRCA or PALB2 mutations
October 23, 2025
Now Enrolling: EA8231 Study for Patients With Bladder Cancer That Has Progressed Following Treatment
This phase 3 clinical trial is testing a new treatment approach for patients with treatment-refractory locally-advanced or metastatic urothelial cancer
October 17, 2025
Summaries of two clinical trials presented at the 2025 World Conference on Lung Cancer
August 28, 2025
This clinical trial aims to improve outcomes by utilizing novel myeloma targeting therapy to reverse kidney failure
July 10, 2025
This clinical trial aims to improve survival for high-risk patients by adding a targeted therapy to standard post-surgery immunotherapy
June 25, 2025
This clinical trial is evaluating a new drug combination for patients with B-cell lymphoma that has relapsed after remission or no longer responds to standard treatment
February 9, 2024
This phase 2 trial is evaluating the combination of two different types of targeted drugs—sotorasib and panitumumab—that appear to be synergistic
June 30, 2023
This phase 2 trial is evaluating the activity of nilotinib-paclitaxel in patients with solid tumors and exploring predictive biomarkers of response and resistance
April 19, 2023
This phase 2 study is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
December 20, 2022
This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population